Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90


Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.

Celegato M, Borghese C, Casagrande N, Carbone A, Colombatti A, Aldinucci D.

Leuk Lymphoma. 2014 Jan;55(1):149-59. doi: 10.3109/10428194.2013.800196. Epub 2013 Jun 12.


NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.

Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C, Krönke M.

Blood. 2007 May 1;109(9):3982-8. Epub 2006 Dec 21.


IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.

Aldinucci D, Celegato M, Borghese C, Colombatti A, Carbone A.

Br J Haematol. 2011 Jan;152(2):182-90. doi: 10.1111/j.1365-2141.2010.08497.x. Epub 2010 Nov 28.


The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.

Celegato M, Borghese C, Umezawa K, Casagrande N, Colombatti A, Carbone A, Aldinucci D.

Cancer Lett. 2014 Jul 10;349(1):26-34. doi: 10.1016/j.canlet.2014.03.030. Epub 2014 Apr 2.


IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma.

Aldinucci D, Rapana' B, Olivo K, Lorenzon D, Gloghini A, Colombatti A, Carbone A.

Br J Haematol. 2010 Jan;148(1):115-8. doi: 10.1111/j.1365-2141.2009.07945.x. Epub 2009 Oct 11.


Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.

Voutsadakis IA, Patrikidou A, Tsapakidis K, Karagiannaki A, Hatzidaki E, Stathakis NE, Papandreou CN.

Int J Colorectal Dis. 2010 Jul;25(7):795-804. doi: 10.1007/s00384-010-0939-0. Epub 2010 Apr 16.


Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.

Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.

Cancer Res. 2008 Aug 15;68(16):6698-707. doi: 10.1158/0008-5472.CAN-08-0257.


The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.

Cancer Res. 2007 Mar 15;67(6):2783-90.


Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.

Eur J Haematol. 2008 Feb;80(2):133-42. Epub 2007 Dec 20.


Bortezomib downregulates MGMT expression in T98G glioblastoma cells.

Vlachostergios PJ, Hatzidaki E, Stathakis NE, Koukoulis GK, Papandreou CN.

Cell Mol Neurobiol. 2013 Apr;33(3):313-8. doi: 10.1007/s10571-013-9910-2. Epub 2013 Jan 20.


PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.

Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW, Ma J, Garcia JF, Song YP, Li JM, Shen ZX, Chen Z, Janin A, Chen SJ.

Blood. 2008 Apr 1;111(7):3867-71. doi: 10.1182/blood-2007-08-108654. Epub 2008 Jan 30.


Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A, Pizzi M, Cappellesso R, Zaffino F, Di Maggio SA, Cabrelle A, Marino F, Zambello R, Trentin L, Adami F, Gurrieri C, Semenzato G, Piazza F.

PLoS One. 2013 Sep 27;8(9):e75280. doi: 10.1371/journal.pone.0075280. eCollection 2013.


The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.

Böll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, Engert A, Pogge von Strandmann E.

Blood. 2005 Sep 1;106(5):1839-42. Epub 2005 May 5.


Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.

Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN.

Int J Urol. 2012 Jun;19(6):565-74. doi: 10.1111/j.1442-2042.2012.02967.x. Epub 2012 Feb 10.


[Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].

Shang J, Chen ZZ, Wu WB, Wei TN, Chen WM.

Zhonghua Xue Ye Xue Za Zhi. 2012 Nov;33(11):911-6. Chinese.


Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.

Tang ZY, Wu YL, Gao SL, Shen HW.

J Surg Res. 2008 Mar;145(1):111-23. Epub 2007 Aug 22.


Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.

Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G, Bachelez H, Michel L.

Blood. 2006 Mar 15;107(6):2354-63. Epub 2005 Oct 11.


The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.

Buglio D, Mamidipudi V, Khaskhely NM, Brady H, Heise C, Besterman J, Martell RE, MacBeth K, Younes A.

Br J Haematol. 2010 Nov;151(4):387-96. doi: 10.1111/j.1365-2141.2010.08342.x. Epub 2010 Sep 29.


TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.

Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA.

Mol Cancer Ther. 2007 Jul;6(7):2103-12.

Supplemental Content

Support Center